Onward Medical N.V. (63E.F)
| Previous close | 4.5600 |
| Open | 4.5700 |
| Bid | 4.6600 x N/A |
| Ask | 5.1800 x N/A |
| Day's range | 4.5700 - 4.7400 |
| 52-week range | 1.9950 - 6.5400 |
| Volume | |
| Avg. volume | 154 |
| Market cap | 173.139M |
| Beta (5Y monthly) | 0.84 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
ONWARD® Medical Announces Results of Annual General Meeting of Shareholders
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Shareholders approve all proposed resolutions EINDHOVEN, the Netherlands, June 13, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces all proposed resolutions at its
- GlobeNewswire
ONWARD® Medical Reports Q1 2024 Update and Year-to-Date Highlights
Nature Medicine published Up-LIFT pivotal trial results Submitted FDA De Novo application for ARC-EX® System Successfully raised EUR 20M in equity capital EINDHOVEN, the Netherlands, May 23, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), a medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today provided a Q1 2024 business update. “This week’s publication of Up-L
- GlobeNewswire
ONWARD® Medical to Host Webcast to Share Details from its Up-LIFT Trial and Yesterday’s Nature Medicine Publication
Nature Medicine published Up-LIFT pivotal trial results Company will discuss pivotal trial results during webcast this week with company leaders and study principal investigators and participants EINDHOVEN, the Netherlands, May 21, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces that on Thursda
